Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well... I can see my shares (what few I have) but I am unable to trade them through Sharebuilder/Capital One...
I guess I'll just have to hold them until it reaches dollar-land....
ummm... up 47%?
WOOT WOOT!
THanks!
my view... please correct me if I am wrong...
... now that we have the results, RGBP still needs to present it (deliver it) to the FDA. The FDA then has 30 days to decline. If they do not decline, it is automatically approved to start trials.
Do I have this right?
TIA
-Michele
Wow... they asked her! The Salk Institute! IMPRESSIVE!!
RGBP
Thanks, Sparkle... I'll keep my fingers crossed!
-Michele
Still here, holding a small bit compared to the rest of you.
Do we know anymore about the settlement? I haven't been paying much attention lately...
TIA
Michele
Has anyone looked at little sis ENTBD....? What would this mean (if anything) for RGBP?
thanks, guys! Been holding this for a few years now... let's hope something good happens!
Can someone please explain the Zander side of things? Is this a spin off? Will ENTB holders get "gitfed" shares of Zander? I am a bit lost on this...
TIA
What dividend was "the last one"... and was it on the RGBP common shares?
Can anyone tell me when we may expect a value to be on the Preferred Shares?
All three (3) tickers are up... ENTB, BMSN, & RGBP
ridiculous, huh? I am stuck with 1.5 million shares worth nothing!
Think I can get out of this today?
what caused the jump?
I have been involved in a few spin offs with these penny stocks... let's hope this one is profitable!
Best of luck to us all!
OMG.... so just for clarification... in May I sold 500 shares for $2.45 ($1,218) and in July I sold 1,060 for $1.20 ($1,265)... So am I to understand that if I hadn't sold, my 1,560 shares (@ $2,400) would be worth 1.56 shares of a whopping $7.00?
HOLY COW...
Thank you... I understand what a spin-off is, I simply missed the PR about it. Does anyone know what the ratio is or when it will happen?
I no longer have a position here as I sold the last of my shares back in May 2014 and July 2014... I popped in to take a look and saw a price of $7.00!? Was there a reverse split? Can someone tell me how much?
TIA
-Michele
I'm sorry... I missed something... what spin off are people talking about?
TIA
-Michele
WTH??? Up 99,900% to $0.001??? How did that happen!?
Confirmed!! Got mine in ShareBuilder account.... Woo hoo....
Here is the response I received from a ShareBuilder Rep about the preferred shares...
Sherry Rasyidi:
From Panda on RGBP Board.... any thoughts?
I just got off with ShareBuilder... they don't show them yet.... !!!!
OK, PH is upon us.... Let's go RGBP!!!!
Ahhh, thanks... and when is your Birthday again?
I am confused... I understand the divy on RGBP, but is there also a divy on BMSN?
I have been trying to keep up with all the posts, but I have obviously missed the information regarding the divy. Can someone please tell me what it's about?
Thanks in advance
My Birthday is tomorrow! Can it be a Happy Birthday for us!!????
I'm still here... been here for a while now... only check in now and then....
Question...
I was checking in to see where this was since I sold my shares on 5/30 for $1.20 and 7/9 for $2.45... (I have no shares in this)... I am curious to know if there was another split? How the hell is the price so low?
Just got an ALERT for AXLX.... 24 minutes ago... From 123StockAlerts.com
Hello Traders,
Looks like AXLX is ready to stir things up today as it is already heating up pre-market!! Time for another MONSTER!! Make sure you watch AXLX closely at the Opening Bell!!
Last Night's e-mail:
We are back on track with Thursday's Play showing us REAL Possible GAINS of OVER 100% From Thursday into Friday and our Momentum Monster on Friday moving EASY 20-40% REAL Possible Gains in just an hour!! Let's keep things Rocking with a NEW MONSTER for MONDAY 1/12/15!!
My New Play is: "AXLX" Axiologix Inc.
Just to start things off this Play showed Revenues of OVER $6MM in 2014!!!
Axiologix Set to Report Full Year Revenues of $6.1 Million for Fiscal Year Ending May 31, 2014 - Up 720% From the Previous Year
ATLANTA, June 17, 2014 /PRNewswire/ -- Axiologix, Inc. (www.axiologix.net) (OTC Pinks: AXLX), an International Technology and Services Organization focused on delivering 'Cloud' Products and Services, today provides guidance on full year revenues.
Axiologix is set to report Full Year revenues of $6.1 million for the twelve months ending May 31, 2014, an increase of 720% from the prior year ended May 31, 2013. The main reason for the increased revenues during the year was an additional $5.5 million reported for the five months following the acquisition of iWorld Services in November 2013. Full calendar year revenues for iWorld Services for 2013 were over $13 million.
Revenue for fiscal Q4 ending May 31, 2014 was up 1,300% year-on-year.
The Company is currently completing a Form-10 with the U.S. Securities and Exchange Commission ("SEC") that will return the company to full reporting status. The filing is expected to be completed by the end of June, 2014 and will include audited financials statements for May 31, 2013 and 2012 respectively and a review of the period to February 28, 2014. Full year results will be filed with the SEC within standard reporting timelines once the Form-10 is deemed effective.
Vincent Browne, Chairman and Chief Executive of Axiologix, Inc. said , "We are clearly very pleased with the revenue growth following the successful completion of the iWorld acquisition. We are currently working diligently to complete the longer than originally expected Form-10 process, but are now on the final stretch with it. We are also presently working to close our previously announced iTeknik acquisition, which we anticipate will add a further $10m per year in revenues as well as provide profitable operations from higher margin services. It will also allow us to introduce exciting new higher margin services across the group that will continue to build a sustainable business in the medium to long term".
Full Press Release here: http://finance.yahoo.com/news/axiologix-set-report-full-revenues-120000679.html
How about them Apples???? Not pretty bad for a company that's trading at just a Nickel!!
About Axiologix, Inc.
Axiologix, Inc. (OTC Pinks: AXLX) based in Atlanta, Georgia, USA operates in the rapidly growing Mobile Payments and International Remittance markets. Our key focus is on un-banked and under-banked communities both in the United States and around the World. Together with our innovative strategic partners we provide disruptive 'Cloud' banking services such as 'member-to-member' payments and merchant services using cell phones and the Internet, along with linked debit cards for convenience and international mobile money remittance transfers at a keystroke. Our users have long sought to use more convenient, more inclusive and ultimately more affordable banking services that are currently unavailable to them from regular banking channels. Additional information may be found at www.axiologix.net
Recent Press Release.......
Axiologix, Inc. Launches Exciting Member-to-Member Payments Service As Part Of New Focus On Financial Services Products
ATLANTA, Jan. 7, 2015 /PRNewswire/ -- Axiologix, Inc. (www.axiologix.net) (AXLX ), operating in the rapidly growing Mobile Payments and International Remittance markets, today announces that, following a period of strategic review and business restructuring, it has recently launched a Cloud based 'Member-to-Member' payments service for both consumers and merchants in the United States that provides a mobile device alternative to traditional banking services for those who have so far chosen not to operate a regular bank account. Read more and sign up at www.axiocashgenie.com.
The Genie Cash product suite is offered in conjunction with AllCom, Inc., a veteran of the telecoms and payment processing industry that has developed the solution over many years using patent pending technology and procedures.
The service allows all merchants and small businesses, from online stores to local service providers and eateries, to grow their business and make it easier for customers to pay them. Using Genie Cash, businesses can attract new customers that otherwise could not buy from them using the 'buy online but pay in cash locally' feature; Genie Cash also allow patrons to 'Pay by Text' if they wish, without having to disclose their card details. Genie Cash also delivers a more cost effective solution for these businesses over traditional options by taking in customer payments at less cost than traditional processing fees and subsequently paying their vendors instantly by check with a simple email. No more expensive ACH or wire fees.
Current Report Filing (8-k)
Print
Alert
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 31, 2014
REGEN BIOPHARMA, INC.
(Exact name of small business issuer as specified in its charter)
Nevada 45-5192997
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
Commission File No. 333-191725
4700 Spring Street, St 304, La Mesa, California 91942
(Address of Principal Executive Offices)
(619) 702 1404
(Issuer’s telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01
On December 31, 2014 United States Patent Application No. 14588374 pertaining to the use of molecular interventions to treat myelodysplastic syndrome (MDS) was filed by Dr. Christine Ichim.
United States Patent Application No. 14588374 is a continuation-in-part to pending Non-Provisional U.S. Application Serial Number 13/652,395. All right, title and interest in and to the invention covered by Non-Provisional U.S. Application Serial Number 13/652,395 was assigned to Regen BioPharma, Inc. (“Regen”) by Dr. Ichim on November 20, 2014. In addition all right, title and interest in and to the invention covered by United States Patent Application No. 14588374 is assigned to Regen by Dr. Ichim pursuant to the November 20, 2014 assignment as Application No. 14588374 is a continuation-in-part to pending Non-Provisional U.S. Application Serial Number 13/652,395.
On December 31, 2014 United States Patent Application No. 14588373 pertaining to the suppression of the nuclear receptor NR2F2 using compositions that induce RNA interference for use as cancer stem cell inhibitors as well as cancer stem cell pathway inhibitors was filed by Dr. Christine Ichim.
United States Patent Application No. 14588373 is a continuation-in-part to pending Non-Provisional U.S. Application Serial Number 13/652,395. All right, title and interest in and to the invention covered by Non-Provisional U.S. Application Serial Number 13/652,395 was assigned to Regen BioPharma, Inc. by Dr. Ichim on November 20, 2014. In addition all right, title and interest in and to the invention covered by United States Patent Application No. 14588373 is assigned to Regen by Dr. Ichim pursuant to the November 20, 2014 assignment as Application No. 14588373 is a continuation-in-part to pending Non-Provisional U.S. Application Serial Number 13/652,395.
Item 9.01 Exhibits.
Exhibit No. Description of Exhibit
10.1
Assignment (incorporated by reference to Exhibit 10.1 of Regen Biopharma, Inc.’s Form 8-K filed November 25, 2014)
8K
Current Report Filing (8-k)
Print
Alert
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 31, 2014
REGEN BIOPHARMA, INC.
(Exact name of small business issuer as specified in its charter)
Nevada 45-5192997
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
Commission File No. 333-191725
4700 Spring Street, St 304, La Mesa, California 91942
(Address of Principal Executive Offices)
(619) 702 1404
(Issuer’s telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01
On December 31, 2014 United States Patent Application No. 14588374 pertaining to the use of molecular interventions to treat myelodysplastic syndrome (MDS) was filed by Dr. Christine Ichim.
United States Patent Application No. 14588374 is a continuation-in-part to pending Non-Provisional U.S. Application Serial Number 13/652,395. All right, title and interest in and to the invention covered by Non-Provisional U.S. Application Serial Number 13/652,395 was assigned to Regen BioPharma, Inc. (“Regen”) by Dr. Ichim on November 20, 2014. In addition all right, title and interest in and to the invention covered by United States Patent Application No. 14588374 is assigned to Regen by Dr. Ichim pursuant to the November 20, 2014 assignment as Application No. 14588374 is a continuation-in-part to pending Non-Provisional U.S. Application Serial Number 13/652,395.
On December 31, 2014 United States Patent Application No. 14588373 pertaining to the suppression of the nuclear receptor NR2F2 using compositions that induce RNA interference for use as cancer stem cell inhibitors as well as cancer stem cell pathway inhibitors was filed by Dr. Christine Ichim.
United States Patent Application No. 14588373 is a continuation-in-part to pending Non-Provisional U.S. Application Serial Number 13/652,395. All right, title and interest in and to the invention covered by Non-Provisional U.S. Application Serial Number 13/652,395 was assigned to Regen BioPharma, Inc. by Dr. Ichim on November 20, 2014. In addition all right, title and interest in and to the invention covered by United States Patent Application No. 14588373 is assigned to Regen by Dr. Ichim pursuant to the November 20, 2014 assignment as Application No. 14588373 is a continuation-in-part to pending Non-Provisional U.S. Application Serial Number 13/652,395.
Item 9.01 Exhibits.
Exhibit No. Description of Exhibit
10.1
Assignment (incorporated by reference to Exhibit 10.1 of Regen Biopharma, Inc.’s Form 8-K filed November 25, 2014)
$3 a share? Why? How? When? What makes you say that?
What is going on here?
ok, I'll bite... what is happening here?